Cargando…

Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis

The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA crite...

Descripción completa

Detalles Bibliográficos
Autores principales: Boman, Antonia, Kokkonen, Heidi, Ärlestig, Lisbeth, Berglin, Ewa, Rantapää-Dahlqvist, Solbritt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/
https://www.ncbi.nlm.nih.gov/pubmed/28190118
http://dx.doi.org/10.1007/s10067-017-3570-4
_version_ 1783230903347052544
author Boman, Antonia
Kokkonen, Heidi
Ärlestig, Lisbeth
Berglin, Ewa
Rantapää-Dahlqvist, Solbritt
author_facet Boman, Antonia
Kokkonen, Heidi
Ärlestig, Lisbeth
Berglin, Ewa
Rantapää-Dahlqvist, Solbritt
author_sort Boman, Antonia
collection PubMed
description The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and C-reactive protein were regularly recorded. Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed in plasma at baseline using ELISAs. Data on gene polymorphism for sclerostin and RANKL were extracted from Immunochip analysis. Sex- and age-matched controls (n = 71) were identified from the Medical Biobank of Northern Sweden. The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals. Sclerostin was significantly increased in female patients 0.59 (0.47–0.65) ng/mL compared with female controls 0.49 (0.4–0.65) ng/mL (p < 0.02). RANKL concentration was related to the Larsen score at baseline (p < 0.01), after 24 months (p < 0.001), and to radiological progression at 24 months (p < 0.001). Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. The concentration of RANKL was related to the Larsen score at baseline, at 24 months, and radiological progression at 24 months particularly in anti-CCP2-positive patients, while the concentration of sclerostin was unrelated to radiological findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10067-017-3570-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5400786
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-54007862017-05-08 Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis Boman, Antonia Kokkonen, Heidi Ärlestig, Lisbeth Berglin, Ewa Rantapää-Dahlqvist, Solbritt Clin Rheumatol Original Article The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and C-reactive protein were regularly recorded. Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed in plasma at baseline using ELISAs. Data on gene polymorphism for sclerostin and RANKL were extracted from Immunochip analysis. Sex- and age-matched controls (n = 71) were identified from the Medical Biobank of Northern Sweden. The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals. Sclerostin was significantly increased in female patients 0.59 (0.47–0.65) ng/mL compared with female controls 0.49 (0.4–0.65) ng/mL (p < 0.02). RANKL concentration was related to the Larsen score at baseline (p < 0.01), after 24 months (p < 0.001), and to radiological progression at 24 months (p < 0.001). Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. The concentration of RANKL was related to the Larsen score at baseline, at 24 months, and radiological progression at 24 months particularly in anti-CCP2-positive patients, while the concentration of sclerostin was unrelated to radiological findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10067-017-3570-4) contains supplementary material, which is available to authorized users. Springer London 2017-02-11 2017 /pmc/articles/PMC5400786/ /pubmed/28190118 http://dx.doi.org/10.1007/s10067-017-3570-4 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Boman, Antonia
Kokkonen, Heidi
Ärlestig, Lisbeth
Berglin, Ewa
Rantapää-Dahlqvist, Solbritt
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
title Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
title_full Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
title_fullStr Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
title_full_unstemmed Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
title_short Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
title_sort receptor activator of nuclear factor kappa-b ligand (rankl) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/
https://www.ncbi.nlm.nih.gov/pubmed/28190118
http://dx.doi.org/10.1007/s10067-017-3570-4
work_keys_str_mv AT bomanantonia receptoractivatorofnuclearfactorkappabligandranklbutnotsclerostinorgenepolymorphismsisrelatedtojointdestructioninearlyrheumatoidarthritis
AT kokkonenheidi receptoractivatorofnuclearfactorkappabligandranklbutnotsclerostinorgenepolymorphismsisrelatedtojointdestructioninearlyrheumatoidarthritis
AT arlestiglisbeth receptoractivatorofnuclearfactorkappabligandranklbutnotsclerostinorgenepolymorphismsisrelatedtojointdestructioninearlyrheumatoidarthritis
AT berglinewa receptoractivatorofnuclearfactorkappabligandranklbutnotsclerostinorgenepolymorphismsisrelatedtojointdestructioninearlyrheumatoidarthritis
AT rantapaadahlqvistsolbritt receptoractivatorofnuclearfactorkappabligandranklbutnotsclerostinorgenepolymorphismsisrelatedtojointdestructioninearlyrheumatoidarthritis